WallStreetZenWallStreetZen

NASDAQ: PSNL
Personalis Inc Stock Forecast, Predictions & Price Target

Analyst price target for PSNL

Based on 1 analyst offering 12 month price targets for Personalis Inc.
Min Forecast
$3.50+180%
Avg Forecast
$3.50+180%
Max Forecast
$3.50+180%

Should I buy or sell PSNL stock?

Based on 1 analyst offering ratings for Personalis Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PSNL stock forecasts and price targets.

PSNL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-11

1 of 1

Forecast return on equity

Is PSNL forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is PSNL forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

PSNL revenue forecast

What is PSNL's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$74.0M+0.67%
Avg 2 year Forecast
$86.6M+17.85%
Avg 3 year Forecast
$144.1M+96.06%
PSNL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PSNL revenue growth forecast

How is PSNL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
22.09%
Industry
7.32%
Market
9.92%
PSNL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PSNL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PSNL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
PSNL$1.25$3.50+180.00%Buy
PRE$4.97$9.00+81.09%Strong Buy
ENZ$1.07N/AN/A
VNRX$0.89$3.50+293.26%Strong Buy
DRIO$1.47$4.00+172.11%Strong Buy

Personalis Stock Forecast FAQ

Is Personalis Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PSNL) stock is to Buy PSNL stock.

Out of 1 analyst, 0 (0%) are recommending PSNL as a Strong Buy, 1 (100%) are recommending PSNL as a Buy, 0 (0%) are recommending PSNL as a Hold, 0 (0%) are recommending PSNL as a Sell, and 0 (0%) are recommending PSNL as a Strong Sell.

If you're new to stock investing, here's how to buy Personalis stock.

What is PSNL's revenue growth forecast for 2024-2026?

(NASDAQ: PSNL) Personalis's forecast annual revenue growth rate of 22.09% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Personalis's revenue in 2024 is $73,481,000.On average, 3 Wall Street analysts forecast PSNL's revenue for 2024 to be $3,735,974,685, with the lowest PSNL revenue forecast at $3,726,681,969, and the highest PSNL revenue forecast at $3,743,954,299. On average, 3 Wall Street analysts forecast PSNL's revenue for 2025 to be $4,373,636,787, with the lowest PSNL revenue forecast at $3,873,648,286, and the highest PSNL revenue forecast at $4,975,643,144.

In 2026, PSNL is forecast to generate $7,276,044,784 in revenue, with the lowest revenue forecast at $5,456,339,160 and the highest revenue forecast at $9,095,750,409.

What is PSNL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PSNL) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of N/A.

What is PSNL's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PSNL price target, the average PSNL price target is $3.50, with the highest PSNL stock price forecast at $3.50 and the lowest PSNL stock price forecast at $3.50.

The Wall Street analyst predicted that Personalis's share price could reach $3.50 by Apr 11, 2025. The average Personalis stock price prediction forecasts a potential upside of 180% from the current PSNL share price of $1.25.

What is PSNL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PSNL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.